In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.
The recent rise in colorectal cancer incidence and mortality in younger patients has sparked a serious discussion about strategies to increase screening uptake and adherence, raising questions about the role of noninvasive tests versus the traditional “gold standard,” colonoscopy.
The past year has seen a multitude of FDA approvals, ranging from IL-23 and JAK inhibitors to biologics and subcutaneous treatment administrations, that have helped redefine what it means to treat IBD.